featured
Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Hidradenitis Suppurativa
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Lancet 2024 Jun 08;403(10443)2504-2519, AB Kimball, GBE Jemec, CJ Sayed, JS Kirby, E Prens, JR Ingram, A Garg, AB Gottlieb, JC Szepietowski, FG Bechara, EJ Giamarellos-Bourboulis, H Fujita, R Rolleri, P Joshi, P Dokhe, E Muller, L Peterson, C Madden, M Bari, CC ZouboulisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.